A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2026

Conditions

Relapse Multiple Myeloma

Interventions

DRUG

CS1 Targeted CAR T-cells

Each subject receive CS1 Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER